Susquehanna International Group, LLP Inhibikase Therapeutics, Inc. Transaction History

Susquehanna International Group, LLP

  • $560 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023
BUY
$0.45 - $5.41 $13,795 - $165,848
30,656 New
30,656 $15,000
Q2 2022

Aug 15, 2022
SELL
$0.63 - $1.44 $8,036 - $18,368
-12,756 Closed
0 $0
Q1 2022

May 16, 2022
BUY
$1.03 - $1.77 $13,138 - $22,578
12,756 New
12,756 $19,000

Others Institutions Holding IKT

# of Institutions
2
Shares Held
1.03M
Call Options Held
0
Put Options Held
0
View Full List

About Inhibikase Therapeutics, Inc.

IKT Quotes by TradingView
  • Ticker IKT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,227,100
  • Market Cap $80.7M
  • Description
  • Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointes...
More about IKT
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email